Impact of PET and CT in PET/CT Studies for Staging and Evaluating Treatment Response in Bone and Soft Tissue Sarcomas

Piperkova, E.; Mikhaeil, Mounir; Mousavi, Ali; Libes, Richard; Viejo-Rullan, Francisco; Lin, Henry C.; Rosen, Gerald; Abdel‐Dayem, Hussein M.

doi:10.1097/rlu.0b013e3181966f9d

Cited by 60 publications

(30 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This recommendation is in accord with a meta-analysis by Piperkova et al (45), which showed 18 F-FDG PET to be more accurate than CT for initial staging, restaging, and treatment response assessment. In a brief report of 3 cases, Schuler et al (46) presented their first experiences using combined PET/MR for high-risk sarcomas.…”

Section: Soft-tissue Tumorssupporting

confidence: 71%

Potential Pediatric Applications of PET/MR

et al. 2014

View full text Add to dashboard Cite

Medical imaging with multimodality and whole-body technologies has continuously improved in recent years. The advent of combined modalities such as PET/CT and PET/MR offers new tools with an exact fusion of molecular imaging and high-resolution anatomic imaging. For noninvasive pediatric diagnostics, molecular imaging and whole-body MR have become important, especially in pediatric oncology. Because it has a lower radiation exposure than PET/CT, combined PET/MR is expected to be of special use in pediatric diagnostics. This review focuses on possible pediatric applications of PET/MR hybrid imaging, particularly pediatric oncology and neurology but also the diagnosis of infectious or inflammatory diseases.

show abstract

Section: Soft-tissue Tumorssupporting

confidence: 71%

Potential Pediatric Applications of PET/MR

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Of the 1,310 articles screened, 16 (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21) were selected for the final analysis (Fig. 1).…”

Section: Resultsmentioning

confidence: 99%

Positron emission tomography/computed tomography for osseous and soft tissue sarcomas: A systematic review of the literature and meta-analysis

Muheremu

Amudong

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. In order to elucidate the value of positron emission tomography (PET)/computed tomography (CT) in the clinical diagnosis and treatment of osseous and soft tissue malignancies, two authors independently searched the PubMed, Medline, Elsevier, Embase and Cochrane Library databases for literature published between January 2003 and February 2016, using the key words 'PET/CT', 'positron emission tomography/computed tomography', 'osseous sarcoma', 'bone tumor', 'soft tissue sarcoma' and 'neoadjuvant', to identify prospective and retrospective studies on the applicability of PET/CT on the clinical diagnosis of bone and soft tissue lesions, and evaluation of their response to neoadjuvant therapies. Data were independently extracted by the two authors and any disagreements were resolved by a third author when necessary. Extracted data were analyzed by Meta-Disc 1.6 software. As a result, 16 trials with a total of 883 patients and 2,214 lesions were included in the present study. The overall diagnostic accuracy of PET/CT exhibited a sensitivity and specificity of 0.90 (0.86-0.92) and 0.89 (0.85-0.92), respectively, and the effect of neoadjuvant therapy was assessed with a sensitivity and specificity of 0.79 (0.30-0.93) and 0.79 (0.69-0.89), respectively. Thus, it may be concluded from the present study that PET/CT is a reliable imaging method to be applied in the diagnosis and treatment of osseous and soft tissue malignancies.

show abstract

“…MRI, whole-body CT, and bone scintigraphy or a combination of these methods is applied for restaging of patients with soft-tissue sarcoma. A metaanalysis on the diagnostic performance of 18 F-FDG PET/CT reported 100% sensitivity, 96% specificity, 99% PPV, 100% NPV, and 99% overall accuracy for restaging sarcoma patients (28). In the same analysis, 18 F-FDG PET was more accurate than stand-alone CT.…”

Section: Soft-tissue Sarcomamentioning

confidence: 55%

Oncologic PET/MRI, Part 2: Bone Tumors, Soft-Tissue Tumors, Melanoma, and Lymphoma

Buchbender

Heusner²,

Lauenstein³

et al. 2012

J Nucl Med

151

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to describe (1) the advantages and disadvantages of PET/MRI in oncologic applications in comparison to conventional imaging methods and PET/CT; (2) the limitations of PET/MRI compared with invasive staging procedures (biopsy); and (3) the metabolic-anatomic imaging procedure of choice (PET/MRI vs. PET/CT) based on tumor entity and location.Financial Disclosure: The authors of this article have indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNM designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credit. Physicians should claim only credit commensurate with the extent of their participation in the activity.For CE credit, participants can access this activity through the SNM Web site (http://www.snm.org/ce_online) through August 2013.With integrated whole-body PET/MRI, a novel metabolicanatomic imaging technique recently has been introduced into clinical practice. This review addresses PET/MRI of bone tumors, soft-tissue sarcoma, melanoma, and lymphoma. If PET/ MRI literature is not yet available for some types of tumors, potential indications are based on available PET/CT and MRI data. PET/MRI seems to be of benefit in T-staging of primary bone tumors and soft-tissue sarcomas. With regard to N-staging, PET/MRI can be considered similarly accurate to PET/CT when applied as a whole-body staging approach. M-staging will benefit from MRI accuracy in the brain, the liver, and bone. Imagi ng plays a key role in diagnosis and staging in oncology. Evaluation of local tumor extent and detection of potential locoregional lymph node or distant metastases according to the periodically revised standardized TNM cancer staging system (1) directly affects patient care by defining the most suitable therapy. With integrated wholebody PET/MRI, a new metabolic-anatomic imaging modality has been introduced into clinical practice. Despite the fact that the solution of basic problems, such as adequate MRI-based attenuation correction, is still a work in progress (2), reports on initial clinical experiences with PET/MRI in oncology are already available. In this second part of our review on PET/MRI in oncologic applications, we summarize the available first experiences with PET/ MRI in bone tumors, soft-tissue sarcoma, melanoma, and lymphoma. In fields where PET/MRI data are lacking, we outline the potential role of PET/MRI on the basis of the PET/CT and MRI literature. To provide further information on PET/MRI, we refer to our own unpublished experiences with PET

show abstract

Impact of PET and CT in PET/CT Studies for Staging and Evaluating Treatment Response in Bone and Soft Tissue Sarcomas

Abstract: In BSTS for the purpose of initial staging, ETR, short-term, or long-term restaging, FDG-PET is more accurate than CT. Combined PET/CT has higher accuracy than either alone.

Cited by 60 publications

References 18 publications

Potential Pediatric Applications of PET/MR

Potential Pediatric Applications of PET/MR

Positron emission tomography/computed tomography for osseous and soft tissue sarcomas: A systematic review of the literature and meta-analysis

Oncologic PET/MRI, Part 2: Bone Tumors, Soft-Tissue Tumors, Melanoma, and Lymphoma

Contact Info

Product

Resources

About